Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference

Tuesday, January 6, 2009 General News J E 4
SAN DIEGO, Jan. 6 Orexigen(R) Therapeutics, Inc.(Nasdaq: OREX), a biopharmaceutical company focused on the treatment ofobesity, today announced that the Company will be speaking at the 27th AnnualJ.P. Morgan Healthcare Conference. The details are as follows:

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on thetreatment of obesity. The Company's lead combination product candidates areContrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is inthe later stages of Phase 2 clinical development. Each product candidate isdesigned to act on a specific group of neurons in the central nervous systemwith the goal of achieving appetite suppression and sustained weight loss.Further information about the company can be found at Monday, January 12, 2009 Time: 8:00 a.m. - 8:30 a.m. Pacific Location: Westin St. Francis, San Francisco, California Webcast link:

SOURCE Orexigen Therapeutics, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
HealthCentral Amasses Top Three Online Health Audi...
Star Scientific Announces Successful Completion of...